Delfi Diagnostics is a company dedicated to saving lives through early cancer detection using their innovative fragmentomics technology. Delfi has pioneered breakthroughs in machine learning and fragmentomics by analyzing cell-free DNA fragments from simple liquid biopsy blood samples to support early-stage cancer detection. Their scalable approach allows them to quickly scan millions of data points to identify previously unrecognized cancer-associated DNA fragments. Delfi Diagnostics collaborates with leading cancer biology, bioinformatics, and machine learning experts to advance their technology. The company has initiated a large-scale clinical trial, CASCADE-LUNG, to validate the effectiveness of its approach.
11 - 50 employees
Founded 2018
𧬠Biotechnology
βοΈ Healthcare Insurance
π Pharmaceuticals
π° $225M Series B on 2022-07
September 26
Lead software development for cancer detection products at DELFI Diagnostics.
πΊπΈ United States β Remote
π΅ $198k - $300k / year
π° $225M Series B on 2022-07
β° Full Time
π Senior
β Product Manager
π¦ H1B Visa Sponsor